Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 13/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 7/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831504 | 0.85 | RPS6KA3 (0.40) | RPS6KA3MAPKAPK2RPS6KA2CSNK2A2CSNK2B | |
| SCHEMBL4830030 | 0.80 | SLC22A12 (0.35) | RPS6KA3MAPKAPK2RPS6KA2AOC3CSNK2A2 | |
| SCHEMBL4826644 | 0.79 | RPS6KA3 (0.39) | RPS6KA3MAPKAPK2RPS6KA2CSNK2A2CSNK2B | |
| SCHEMBL4829961 | 0.75 | SMN1; SMN2 (0.40) | RPS6KA3MAPKAPK2RPS6KA2 | |
| SCHEMBL50870 | 0.72 | POLB (0.39) | RPS6KA3RPS6KA2 | |
| SCHEMBL3073902 | 0.71 | RPS6KA2 (0.41) | RPS6KA3RPS6KA2 | |
| SCHEMBL50820 | 0.70 | RPS6KA3 (0.49) | RPS6KA3RPS6KA2 | |
| SCHEMBL4831486 | 0.69 | RPS6KA3 (0.41) | RPS6KA3MAPKAPK2RPS6KA2CSNK2A2CSNK2B | |
| SCHEMBL3574670 | 0.68 | SRD5A2 (0.50) | RPS6KA3RPS6KA2 | |
| SCHEMBL4830051 | 0.68 | SMN1; SMN2 (0.37) | RPS6KA3MAPKAPK2RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | RPS6KA3 684/4885MAPKAPK2 3899/4885RPS6KA2 984/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | RPS6KA3 684/4885MAPKAPK2 3899/4885RPS6KA2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.